Dose Range‐Finding Studies With Frovatriptan in the Acute Treatment of Migraine
Authors:
- 1 April 2002
- journal article
- clinical trial
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 42 (s2) , 74-83
Abstract
Objective.—To determine the optimum dose of frovatriptan for the acute treatment of migraine. Background.—Frovatriptan is a new triptan developed for the acute treatment of migraine. The dose‐response characteristics and safety of frovatriptan have been investigated across a broad range of doses from 0.5 to 40 mg. Design.—Two randomized, placebo‐controlled, double‐blind, parallel‐group trials, with a total of 1453 patients, were performed to determine the optimal dose of the 5‐HT 1B/1D agonist, frovatriptan, for the acute treatment of migraine. The dose ranges studied were 2.5 to 40 mg in the high‐dose study and 0.5 to 5 mg in the low‐dose study. Results.—At 2 hours postdosing for initial moderate or severe headache (International Headache Society grades 2 or 3), there was an approximate two‐fold difference in the proportion of patients taking frovatriptan doses of 2.5 to 40 mg with mild or no headache compared to placebo. Frovatriptan doses of 0.5 mg and 1 mg were not more effective than placebo at 2 hours postdose, and 2.5 mg was identified as the lowest effective dose for the relief of migraine and accompanying symptoms. Above 2.5 mg, no dose‐response relationship was observed for any efficacy parameters. There was an increase in the incidence of adverse events from 10 mg and above, but the vast majority were rated as mild in severity and did not impact upon tolerability in a significant manner. Conclusions.—Frovatriptan was well tolerated throughout the dose range of 0.5 to 40 mg. The 2.5‐mg dose confers the optimal balance of efficacy and tolerability for the acute treatment of migraine.Keywords
This publication has 11 references indexed in Scilit:
- Frovatriptan: A Review of Drug‐Drug InteractionsHeadache: The Journal of Head and Face Pain, 2002
- Pharmacokinetics and Pharmacodynamics of the Triptan Antimigraine AgentsClinical Pharmacokinetics, 2001
- Efficacy of naratriptan tablets in the acute treatment of migraine: A dose-ranging studyClinical Therapeutics, 2000
- Safety and Tolerability of the Novel 5‐HT 1B/1D Agonist Rizatriptan in MigraineursHeadache: The Journal of Head and Face Pain, 1999
- Pharmacologic Profile and Clinical Efficacy of RizatriptanHeadache: The Journal of Head and Face Pain, 1999
- Effects of the Novel High-Affinity 5-HT1B/1D-Receptor Ligand Frovatriptan in Human Isolated Basilar and Coronary ArteriesJournal of Cardiovascular Pharmacology, 1998
- Tolerability and Efficacy of Naratriptan Tablets with Long-Term Treatment (6 Months)Cephalalgia, 1998
- Naratriptan is Effective and Well Tolerated in the Acute Treatment of Migraine. Results of a Double‐Blind, Placebo‐Controlled, Parallel‐Group StudyHeadache: The Journal of Head and Face Pain, 1997
- Optimizing the dose of zolmitriptan (Zomig,* 311C90) for the acute treatment of migraineNeurology, 1997
- Guidelines for Controlled Trials of Drugs in Migraine. First EditionCephalalgia, 1991